CNTA – centessa pharmaceuticals plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Centessa Pharmaceuticals plc (NASDAQ: CNTA) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $26.00 price target on the stock, up previously from $11.00.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is now covered by analysts at B. Riley. They set a "buy" rating and a $33.00 price target on the stock.
Form SC 13G/A Centessa Pharmaceuticals Filed by: EcoR1 Capital, LLC
Form SC 13G/A Centessa Pharmaceuticals Filed by: BIOTECHNOLOGY VALUE FUND L P
Form 144 Centessa Pharmaceuticals Filed by: SAHA SAURABH
Form 8-K Centessa Pharmaceuticals For: Nov 12
Form 10-Q Centessa Pharmaceuticals For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.